Close Menu
The Business TimesThe Business Times
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
What's On
Macquarie Value Fund Q3 2025 Sales And Purchases

Macquarie Value Fund Q3 2025 Sales And Purchases

7 December 2025
UK snow forecast as Arctic weather blast days away from hitting major cities

UK snow forecast as Arctic weather blast days away from hitting major cities

7 December 2025
Britain’s most expensive Christmas markets boycotted as shoppers slam ‘rip off’ prices

Britain’s most expensive Christmas markets boycotted as shoppers slam ‘rip off’ prices

7 December 2025
Wales school to close as outbreak of vomiting illness impacts hundreds of pupils

Wales school to close as outbreak of vomiting illness impacts hundreds of pupils

7 December 2025
Car tax reduced to £0 for these drivers – see full list of exemptions

Car tax reduced to £0 for these drivers – see full list of exemptions

7 December 2025
Facebook X (Twitter) Instagram
Business Sunday, Dec 7
The Business TimesThe Business Times
Newsletter
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
The Business TimesThe Business Times
Home » Warning over common painkiller as study shows it’s not fit for purpose
News

Warning over common painkiller as study shows it’s not fit for purpose

thebusinesstimes.co.ukBy thebusinesstimes.co.uk12 October 20254 Views
Facebook Twitter LinkedIn Reddit Telegram WhatsApp Pinterest Tumblr VKontakte Email
Warning over common painkiller as study shows it’s not fit for purpose
Share
Facebook Twitter LinkedIn Pinterest Email

Tramadol is typically prescribed to help people cope with moderate to severe pain, usually after an operation or a serious injury. But a new study has cast doubt on how effective it really is

Millions of people turn to prescription medication to help them manage their pain. But now a new study has cast doubt on the efficiency of one popular drug.

Tramadol is typically prescribed to help people cope with moderate to severe pain, usually after an operation or a serious injury. However, it is now being suggested that the medication’s potential risks outweigh its “limited” benefits for chronic pain – and that the use of it should be minimised.

The study, which has been published in the journal BMJ Evidence-Based Medicine, found that tramadol may have a “slight effect” on reducing chronic pain, but that there appears to be little evidence.

“The findings indicate that the benefits of tramadol are questionable or, at the very least, uncertain. Furthermore, evidence suggests the presence of potentially harmful effects,” Dr. Janus Jakobsen, lead author of the study and a clinical professor at the University of Southern Denmark in Copenhagen, said in an email.

READ MORE: Pensioners snorting cocaine skyrockets as UK hospitals in crisisREAD MORE: Sertraline warning as Brits on common medication told ‘avoid this drink’

Tramadol is an opiate and can lead to patients becoming addicted, so it is closely controlled by doctors. In the US, more than 16 million prescriptions were written for tramadol in 2023 alone.

The study team assessed 19 published clinical trials involving over 6,500 people with chronic pain. They examined the impact of the drug on neuropathic pain, osteoarthritis, chronic low back pain, and fibromyalgia. Participants had an average age of 58, with tablets being the main form of medication. The pooled data analysis found that while it eased some pain, Tramadol’s effect was below the threshold of what would be considered clinically effective.

Tramadol can have serious side effects, including cardiac events such as chest pain, heart disease or congestive heart failure, according to the study.

“In 2019, drug use was responsible for approximately 600,000 deaths, with nearly 80 percent of these fatalities associated with opioids and approximately 25 percent resulting from opioid overdose,” it concluded.

“Given these trends and the present findings, the use of tramadol and other opioids should be minimised to the greatest extent possible.”

READ MORE: Doctor warns anyone taking 3 prescription medications to ‘be careful’

“Therefore, alternative treatment options should be considered before prescribing tramadol,” Jakobsen added. “Patients are advised to consult their physicians to determine the most appropriate treatment for their condition. Such treatments should likely be individualised according to the type of chronic pain experienced.”

It comes after a mum spoke out to warn others about the dangers of experimental drug-taking after the sudden death of her teenage son as a result of Tramadol. Kim Webster’s 17-year-old son, Will Horley, died in 2018 after he suffered a fatal reaction to the drug on a night out.

“He was not a ‘druggie’, but one night he went out with a friend and after a few drinks they were offered Tramadol as a recreational high,” Kim shared.

“His friend survived but tragically Will had a reaction and died. It goes to show that drug experimentation can be literally like the flip of a coin; heads you’re OK, tails you’re not. Will had a bright future in front of him in the Army but it was gone in an instant.”

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related Articles

Macquarie Value Fund Q3 2025 Sales And Purchases

Macquarie Value Fund Q3 2025 Sales And Purchases

UK snow forecast as Arctic weather blast days away from hitting major cities

UK snow forecast as Arctic weather blast days away from hitting major cities

Wales school to close as outbreak of vomiting illness impacts hundreds of pupils

Wales school to close as outbreak of vomiting illness impacts hundreds of pupils

Prince William to follow in Diana’s footsteps and take George to help the homeless

Prince William to follow in Diana’s footsteps and take George to help the homeless

Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript

Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript

Massive fire rips through 182-year-old church as flames cause tragic collapse

Massive fire rips through 182-year-old church as flames cause tragic collapse

Average Retirement Plans Can Be Risky: Why Income Investing Is The Practical Solution

Average Retirement Plans Can Be Risky: Why Income Investing Is The Practical Solution

‘Laughter and song will fill my Christmas even though it may be my last’

‘Laughter and song will fill my Christmas even though it may be my last’

UIVM: Unconvincing Blend Of Value And Momentum (NASDAQ:UIVM)

UIVM: Unconvincing Blend Of Value And Momentum (NASDAQ:UIVM)

Editors Picks
UK snow forecast as Arctic weather blast days away from hitting major cities

UK snow forecast as Arctic weather blast days away from hitting major cities

7 December 2025
Britain’s most expensive Christmas markets boycotted as shoppers slam ‘rip off’ prices

Britain’s most expensive Christmas markets boycotted as shoppers slam ‘rip off’ prices

7 December 2025
Wales school to close as outbreak of vomiting illness impacts hundreds of pupils

Wales school to close as outbreak of vomiting illness impacts hundreds of pupils

7 December 2025
Car tax reduced to £0 for these drivers – see full list of exemptions

Car tax reduced to £0 for these drivers – see full list of exemptions

7 December 2025

Subscribe to News

Get the latest finance and business news and updates directly to your inbox.

Latest Posts
Prince William to follow in Diana’s footsteps and take George to help the homeless

Prince William to follow in Diana’s footsteps and take George to help the homeless

7 December 2025
Mum bags M&S shopping for £2.96 instead of £29.55

Mum bags M&S shopping for £2.96 instead of £29.55

7 December 2025
Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript

Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript

7 December 2025
Facebook X (Twitter) Pinterest WhatsApp TikTok Instagram
© 2025 The Business Times. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.